E
DAWN

Ergoteles’s Day One Biopharmaceuticals DAWN Stock Holding History

Ergoteles’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,335
Closed -$299K – 1134
2023
Q1 		$299K Buy
+22,335
New +$436K 0.01% 897
2022
Q3 		– Sell
-56,300
Closed -$1.01M – 1634
2022
Q2 		$1.01M Buy
+56,300
New +$581K 0.03% 538

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Ergoteles's DAWN Position: Q2 2023 in Review

Ergoteles sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 22,335 shares — an estimated $299K sold.

Ergoteles first reported a position in DAWN in Q2 2022 and held it in 2 quarters. The position peaked at $1.01M in Q2 2022. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • Ergoteles reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 22,335 Day One Biopharmaceuticals shares in Q2 2023, an estimated $299K.
  • Ergoteles first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Day One Biopharmaceuticals position peaked at $1.01M in Q2 2022.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.